3199E Posttest: Lunch Symposium - Chronic Antibody-Mediated Rejection

Posttest

This session is supported by an educational grant from CSL Behring.

Please complete these post-test questions so we can assess what you learned at the Cutting Edge of Transplantation. You will be shown the correct answers on the next screen. If you are not claiming ACPE credit, you are not required to "pass" the post-test in order to claim credit, simply provide answers and proceed.

Question Title

* 1. Which of the following is a false statement:

De novo DSA associated ABMR has a worse outcome than memory DSA associated ABMR

The risk of developing memory associated ABMR is related to the pre-transplant antibody titer.

Transplant glomerulopathy is specific for DSA associated ABMR

Transplant glomerulopathy in the presence of active ABMR is a strong predictor of the risk for graft loss

Patients with Chronic active ABMR are at increased risk for graft loss when they have high levels of proteinuria

Question Title

* 2. The key histopathological and molecular correlates of antibody-mediated tissue injury are:

Donor-specific anti-HLA antibody and increased cell free DNA

Microcirculation inflammation and remodelling with increased expression of NK cell and endothelial transcripts

Transplant glomerulopathy with gamma interferon expression

Glomerulitis with macrophage and T cell associated transcripts

Question Title

* 3. Choose the correct statement regarding adaptive trial designs.

Traditional endpoints are used more often than surrogate endpoints

An “umbrella” master protocol involves studying one therapeutic for multiple diseases.

A platform master protocol utilizes one control group to be compared against multiple therapies.

Adaptive trial designs are novel and have not yet been used in medicine.